-
- Posted Wednesday July 27, 2016
Cycle for the Cure raises a record $248,725 for cancer research at TGen
Philanthropists Sherry and Richard Holson are instrumental in securing $100,000 in donations from Guarantee Trust Life
PHOENIX, Ariz. - July 27, 2016 - This year's Cycle for the Cure already was on track to be one of the most successful in its six years of raising cancer research funds for the non-profit Translational Genomics Research Institute (TGen).
But thanks to additional donations generated by Guarantee Trust Life of Glenview, Ill., the 6th annual Cycle for the Cure garnered a record $248,725 for TGen.
The May 1 event, which featured hundreds of dedicated donors spinning on stationary cycles for up to 2 hours at several health clubs in Phoenix and Scottsdale, produced $173,725.
But Vicki Vaughn, Co-Chair of Cycle for the Cure, wasn't finished.
After introducing her friends - Richard S. Holson III, Chairman, CEO and President of Guarantee Trust Life, and his wife, Sherry - to TGen, the Holson's company invited TGen cancer researcher Dr. Will Hendricks and TGen Foundation Vice President Erin Massey to present at Guarantee Trust Life's recent company conference in Arizona. The company was impressed and donated $25,000, part of the initial tally for Cycle for the Cure.
Then, after company officials toured TGen laboratories, they challenged their partners and representatives to donate to Cycle for the Cure. They raised a combined $37,500, which Guarantee Trust Life matched, dollar-for-dollar, adding another $75,000 to the $25,000 the company already donated, bringing the total generated by Guarantee Trust Life to $100,000.
"TGen should be very grateful to my wife, Sherry, and Vicki Vaughn as they were responsible for introducing my company to this amazing organization. We were impressed with, and inspired by, the remarkable people at TGen and the world-class, life-changing research being conducted," said Richard Holson. "And the response by our agents with their contributions was great."
Using genomic sequencing, TGen helps doctors match the appropriate therapy to each patient's DNA profile, producing the greatest patient benefit. This year, Cycle for the Cure raised research funds for work on a revolutionary diagnostic method called "liquid biopsies" - biomarkers in circulating blood - as a means of providing patients and their doctors with early detection of disease.
"We believe everyone should know first-hand about the groundbreaking research going on at TGen, and we encourage everyone to join us in supporting the vital work TGen does," said Vicki Vaughn, who co-chaired Cycle for the Cure with Robyn DeBell.
Village Health Clubs and Studio 360 provided the venues for this year's Cycle for the Cure. In addition, yoga and kinesis classes were included in the fundraising events by Village Health Clubs at its DC Ranch and Camelback locations.
"We are incredibly proud to have merited the dedicated support of volunteer co-chairs Vicki Vaughn and Robyn DeBell," said TGen Foundation President Michael Bassoff. "Their extraordinary leadership, and the generosity of business leaders like Rick Holson and the Guarantee Trust Life company, provides an incredible boost to TGen's cancer research initiatives."
Donations continue to be accepted at www.tgenfoundation.org/cycle. And save the date for next year's 7th annual Cycle for the Cure: April 30, 2017.
# # #
About TGen
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
Media Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
